EVE Health Group Limited (AU:EVE) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
EVE Health Group Limited reports a 3% year-over-year revenue growth for its Meluka Australia brand, reaching $2.1 million despite reduced marketing spend, alongside the successful sale of Jenbrook property and ongoing negotiations for the Robyndale property sale. The company also signals strong customer interest in its new probiotic powder supplement system and aims to unlock capital through divestment of tea tree assets to fuel future growth in the health and wellness sector.
For further insights into AU:EVE stock, check out TipRanks’ Stock Analysis page.